Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 7/20 | 0.72 |
| ▸ | CPA3 | P15088 | 3/20 | 0.70 |
| ▸ | CPB1 | P15086 | 1/20 | 0.70 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | MME | P08473 | 3/20 | 0.65 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.65 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.59 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.59 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.59 |
| ▸ | ANPEP | P15144 | 1/20 | 0.56 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.56 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6469019 | 0.87 | CPA1 (0.70) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL17948789 | 0.87 | CPA1 (0.70) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL1177225 | 0.87 | CPA1 (0.70) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL28484063 | 0.87 | CPA1 (0.70) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Bromide SCHEMBL1177352 | 0.86 | CPA1 (0.68) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL28102506 | 0.84 | CPA1 (1.00) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL7286643 | 0.84 | CPA1 (0.70) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL10076047 | 0.84 | CPA1 (0.70) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL7540821 | 0.83 | CPA1 (0.72) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL9029155 | 0.83 | CPA1 (0.72) | CPA1CPA3CPB1CPB2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200087648-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | NYSNOBIO IRELAND DAC (IE) | 2020-03-19 | — | — | US | disclosed |
| US-10155936-B2 | Parkin ligase activation methods and compositions | An2H Discovery Limited (IE) | 2018-12-18 | — | — | US | disclosed |
| US-20160160205-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | An2H Discovery Limited (IE) | 2016-06-09 | — | — | US | disclosed |
| US-20160160205-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | An2H Discovery Limited (IE) | 2016-06-09 | — | — | US | disclosed |
| US-20160160205-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | An2H Discovery Limited (IE) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155936-B2 | Parkin ligase activation methods and compositions | PINK1, XIAP, STUB1 | CPA1 3802/4885CPA3 4290/4885CPB1 2398/4885 |
| US-20200087648-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | PINK1, XIAP, STUB1 | CPA1 3802/4885CPA3 4290/4885CPB1 2398/4885 |
| US-20160160205-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | PINK1, XIAP, STUB1 | CPA1 3802/4885CPA3 4290/4885CPB1 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.